Thus, we can conclude ...

Thus, we can conclude that the predictors of efficacy are less disease duration, a smaller number of factors leading to the appearance of fatigue, lower score on the questionnaire fatigue. Conclusion Our results have shown good efficacy in treating patients with Enerion psycho-vegetative syndrome with pronounced asthenic manifestations. The drug was effective in all patients studied, 75% of patients rated as the effect of the drug is very effective, 25% of patients the action of the drug assessed as satisfactory. The drug has good tolerability and convenient dosing form. Enerion has expressed protivoastenicheskim and vegetotropnym effect, normalizes the sleep pattern, normalize the overall mood, improves quality of life, has a pronounced positive impact on the processes of learning and opportunities to operate with new information, improves concentration and performance. Protivoastenichesky Eneriona effect already appears at the end of the first week of admission, and increases during terapii.Enerion can be recommended for use both as monotherapy and as part of combination therapy. References: 1. Wayne AM Diseases of the autonomic nervous system. M. Science 1991. 655 sec. 2. Gnezditsky VV Evoked potentials in clinical practice, Taganrog, 1997. 367. 3. Karelin AA Psychological tests with M. Vlados 2001.247. 4. Oknin VY Clinical and physiological aspects of the pathogenesis of hyperhidrosis: Dis ... Cand. med. Science. M 1991. 5. Raigorodskii DY Practical psychodiagnostics S. Bachrach. 1998. 668. 6. Fedotov AV Clinical and psycho-vegetative features of patients with arterial hypotension: Dis ... Cand. med. Science. M. 2000. 7. Hanin YL A brief guide to the use of scales of reactive and personal anxiety CH.D. Spielberger. L. 1976., 40. 8. Acuna V. The use of salbutamine in a group of university students presenting with a psychosomatic fatigue syndrome Gaz. Med. 1985; 92:1-3. 9. Archard J. A polyvalent approach to the treatment of post-infection asthenia: Arcalion Ther. Pharm.Clin. 1985; l.4: 23-27. 10. Beck A.T., Ward C.M., Mendelsohn M. et al. An inventory for measuring depression Arch. Gen. Psychiat. 1961, 5: 561 -571. 11. Daniel J., Cristol R. The rehabilitation of patient with coronary artery disease: contribution of a new drug Med. Int. 1974; l.9 :53-54. 12. Feuerstein C. Neurophysiological data concerning fatigue. Role of activator reticular formation Entretiens de Bichat. 1992. 13. Martin A. Clinical trials with Arcalion in irritable colon syndrome Vie Med. 1981, 12: 2-3. 14. Spielberger C.D., Gorsuch R.L., Lushene R.E. STAI manual for the State-Trait Anxiety Inventory Consulting. Psychologist. Press. Palo. Alto. 1970. Published with permission from Russian Medical Journal.

Parkinson's Disease

English physician James Parkinson, when he described in 1817, this disease was convinced that the main symptom is a tremor.